Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives.
Four types of bovine liver catalase (CAT) derivatives, succinylated (Suc-CAT), galactosylated (Gal-CAT), mannosylated (Man-CAT), and polyethylene glycol conjugate (PEG-CAT), were synthesized and their pharmacokinetics and therapeutic potential in a hepatic ischemia/reperfusion injury model were studied in mice. About 90% of the CAT enzymatic activity was retained after chemical modification. Biodistribution studies showed that 111indium (111In)-Gal-CAT accumulated selectively in the liver parenchymal cells as 111In-CAT, whereas an increased amount of 111In-Suc-CAT and 111In-Man-CAT was delivered to liver nonparenchymal cells. 111In-PEG-CAT exhibited prolonged retention in plasma. Pharmacokinetic analysis revealed that the hepatic uptake clearances of 111In-Suc-CAT, 111In-Gal-CAT, and 111In-Man-CAT were much greater than that of 111In-CAT, whereas that of 111In-PEG-CAT was very small. In the ischemia/reperfusion injury model, in which hepatic injury was induced by occlusion of the portal vein for 30 min followed by 1 h reperfusion, the elevation of plasma glutamic pyruvic transaminase and glutamic oxaloacetic transaminase levels was slightly inhibited by treatment with native CAT or Gal-CAT. PEG-CAT was less potent. In contrast, Suc-CAT and Man-CAT effectively suppressed the increase in plasma glutamic pyruvic transaminase and glutamic oxaloacetic transaminase. Coinjection of mannosylated superoxide dismutase marginally improved the inhibitory effects of CAT derivatives. These results demonstrate that targeted CAT delivery to liver nonparenchymal cells via chemical modification is a promising approach to prevent hepatic injuries caused by reactive oxygen species. The potential usefulness of combining of CAT and superoxide dismutase derivatives is also demonstrated.
Yabe
Y
Y
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
Nishikawa
M
M
Tamada
A
A
Takakura
Y
Y
Hashida
M
M
D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D002374:Catalase / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D002417:Cattle; D004357:Drug Synergism; D005690:Galactose / Q000737:chemistry; D006651:Histocytochemistry; D007205:Indium Radioisotopes; D007511:Ischemia / Q000473:pathology / Q000517:prevention & control; D008099:Liver / Q000098:blood supply / Q000201:enzymology / Q000473:pathology; D008297:Male; D008358:Mannose / Q000737:chemistry; D051379:Mice; D011092:Polyethylene Glycols / Q000737:chemistry; D015427:Reperfusion Injury / Q000473:pathology / Q000517:prevention & control; D013386:Succinates / Q000737:chemistry; D013482:Superoxide Dismutase / Q000494:pharmacology*; D014018:Tissue Distribution
D007205:Indium Radioisotopes; D013386:Succinates; D011092:Polyethylene Glycols; D002374:Catalase; D013482:Superoxide Dismutase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008358:Mannose; D005690:Galactose